Ginsenoside Rb_(1) improves human nonalcoholic fatty liver disease with liver organoids-on-a-chip  

作　　者：Hui Wang Yue Zhu Pengcheng Shi Xiangyang Li Qingyun Bu Yachun Li Xiaoyan You Guoping Zhao 

机构地区：[1]Master Lab for Innovative Application of Nature Products,National Center of Technology Innovation for Synthetic Biology,Tianjin Institute of Industrial Biotechnology,Chinese Academy of Sciences(CAS),Tianjin 300308,PR China [2]Henan Engineering Research Center of Food Microbiology,College of food and bioengineering,Henan University of Science and Technology,Luoyang 471023,PR China [3]Haihe Laboratory of Synthetic Biology,Tianjin 300308,PR China [4]CAS-Key Laboratory of Synthetic Biology,CAS Center for Excellence in Molecular Plant Sciences,Institute of Plant Physiology and Ecology,Chinese Academy of Sciences,Shanghai 200032,PR China [5]CAS Key Laboratory of Quantitative Engineering Biology,Shenzhen Institute of Synthetic Biology,Shenzhen Institute of Advanced Technology,Chinese Academy of Sciences,Shenzhen 518055,PR China [6]Engineering Laboratory for Nutrition,Shanghai Institute of Nutrition and Health,Chinese Academy of Sciences,Shanghai 200031,PR China

出　　处：《Engineered Regeneration》2024年第3期283-294,共12页再生工程（英文）

基　　金：supported by the Tianjin Synthetic Biotechnology Innovation Capacity Improvement Projects(TSBICIP-CXRC-008);Major Project of Haihe Laboratory of Synthetic Biology(E2M9560201);National Natural Science Foundation of China(32301210&31200035);the China Postdoctoral Science Foundation(No.2022M713330).

摘　　要：Non-alcoholic fatty liver disease(NAFLD),a type of liver disease for which no treatment is currently approved,remains a major concern worldwide.It is manifested as simple hepatocyte steatosis and can develop into inflam-mation,fibrosis,cirrhosis and liver cancer in severe cases.However,due to the lack of appropriate in vitro drug testing platforms,an in-depth understanding of the therapeutic activity of ginsenoside Rb_(1) in NAFLD remains challenging.Here,we proposed a NAFLD model on a liver organoids(LOs)-on-a-chip platform to evaluate the therapeutic effect of ginsenoside Rb_(1) in a dynamic,multi-condition and high-throughput manner.This platform allowed us to reshape certain features such as multicellular types and liver-specific functions of the physiology of the human-relative liver.Free fatty acids(FFAs)-induced LOs displayed typical pathological characteristics of NAFLD progression,including steatosis,oxidative stress,lipid peroxidation,inflammation and fibrosis.With ginsenoside Rb_(1) intervention,these pathological features can be significantly improved,which may provide new insights into the potential mechanisms of NAFLD progression and treatment and suggest the clinical implications for humans.The proposed system enables the formation,differentiation,and function of LOs to serve as a scalable,high-throughput and sensitive drug testing model,to potentially expedite the NAFLD drug discovery.

关 键 词：Nonalcoholic fatty liver Organoid Microfluidic platform Ginsenoside Rb_(1) Biological activity evaluation 

分 类 号：R575.5[医药卫生—消化系统]